Oryzon Genomics appoints Dr Manuel López-Figueroa to its Board as Lead Independent Director
– SPAIN, Barcelona – Oryzon Genomics, S.A. (BME: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, today announced the appointment of Dr Manuel López-Figueroa of Bay City Capital as an independent director.…